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A patient diagnosed with rectal cancer is managed by a mul-
tidisciplinary team in which the radiologist nowadays partic-
ipates as a full sparring partner. His/her imaging findings can
influence the treatment decision-making. The local staging
work-up consists of endorectal ultrasound and/or magnetic
resonance imaging (MRI). The distant staging work-up de-
pends on the local policy but often consists of ultrasound or
computed tomography (CT) of the liver and chest X-ray or
chest CT. While previously all patients underwent a standard-
ised resection, nowadays there is evidence that imaging can
identify the high risk patients with locally advanced rectal
cancer whose tumour is threatening or invading the mesorec-
tal fascia and needs preoperative treatment. This article dis-
cusses the role of the different imaging modalities for local
staging and restaging of rectal cancer and their accuracies
for identifying the risk factors for local recurrence and for
assessing response to preoperative chemoradiotherapy. The
chapter ends with future perspectives in rectal cancer
imaging.
2. Staging modalities
2.1. Endorectal ultrasound (EUS)
The main strength of endorectal (or endoluminal) ultrasound
(EUS) is its excellent spatial resolution, particularly for tissues
that are located near the ultrasound probe. For tissues that
are at a greater distance from the probe, the performance of
EUS is limited. As a result, EUS is accurate mainly for the
assessment of tumour ingrowth in the bowel wall and hence
for the discrimination between tumours that are limited to
the submucosa (T1) versus tumours showing ingrowth in
the muscularis externa (T2). For the evaluation of tumour
penetration into the perirectal fat (i.e. T3 tumours), EUS
reaches results similar to those of MRI and experiences the
same interpretation difficulties; these are related to problems
in distinguishing desmoplastic stranding in T2 tumours from
tumour stranding in T3 tumours (see section on tumour stag-ing). Because of its limited field of view, EUS is less suitable for
the assessment of tumour infiltration into the mesorectal fas-
cia (MRF), tumour extension to the high dorsal pelvic wall and
evaluation of lymph nodes – in particular those in the high
mesorectum along the superior rectal vessels. Furthermore,
it is often difficult to position the ultrasound probe and visu-
alise high and/or stenosing tumours, resulting in inconclusive
results in >10% of patients [1]. Another drawback of EUS com-
pared to cross-sectional imaging techniques is that it is highly
operator-dependent and requires a learning curve before opti-
mal diagnostic performance can be obtained [2]. A potential
benefit of EUS compared to CTand MRI is that it allows for tis-
sue biopsies within one single examination, so that histopa-
thological confirmation can immediately be obtained.
2.2. Computed tomography (CT)
Multislice CT (MSCT) is often considered the modality of first
choice for the distant staging of colorectal cancer (e.g. the
detection of metastatic spread to the liver and/or lungs).
Although it has been proposed by some authors that
simultaneous staging of the rectal tumour using CT as a
‘one-stop-shop’ imaging tool may be beneficial, there are
several drawbacks to the use of CT for assessing the local
tumour status. First of all, the soft tissue contrast of CT is
limited, making it more difficult to distinguish between
tumours limited to the bowel wall and those which have
penetrated the wall. For the assessment of an involved
mesorectal fascia, MSCT is reported to have moderate to poor
accuracy (54–66%). Interestingly, CT can reach fairly good
diagnostic performance for assessing the MRF in tumours
that are located in the mid–high rectum with reported
positive predictive values (PPVs) and negative predictive
values (NPVs) of 86% and 94%, respectively. It is particularly
in low rectal tumours where the limited soft tissue contrast
of CT hampers a reliable differentiation between the tumour
and surrounding structures, resulting in a PPV and NPV of
only 53% and 73% in assessing an involved MRF [3]. For the
evaluation of lymph nodes, CT experiences the same difficul-
ties as MRI and EUS, which are discussed in detail below.
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PET allows for the detection of metabolically active tissues
(e.g. malignant tumours) using tumour-tracing radiopharma-
ceuticals, of which in oncology the glucose analogue 18F-fluo-
rodeoxyglucose (18F-FDG) is the most widely adopted. FDG-PET
can be performed in combination with computed tomography
(CT). This hybrid PET–CT allows for a simultaneous assess-
ment of tumour morphology together with the functional
information from PET. The role of PET(–CT) for the primary
staging of colorectal cancer is limited. Because PET is known
to miss small metastatic lesions in the liver – due to its
limited spatial resolution – it is not recommended as the
staging modality of first choice. However, in patients with
known liver metastases scheduled for liver surgery, PET(–CT)
is very accurate in excluding the presence of extrahepatic le-
sions such as lymph-node and bone metastases. In this con-
text, the use of PET can significantly decrease the number of
futile laparotomies [4]. A second clinical application of PET(–CT)
is the detection of recurrent tumours in patients with a
suspected recurrence after primary surgical treatment for
colorectal cancer. In this setting PET has advantages over
CT, MRI and EUS in differentiating between recurrent tumour
and postoperative scar tissue. Recently there is a growing
interest in the use of PET(–CT) as a tool to predict treatment
response in patients with locally advanced rectal cancer trea-
ted with chemoradiotherapy. Assessment of the decrease in
the standardised uptake value (SUV) during chemoradiation
has been reported by several authors to be a strong indicator
for therapeutic efficacy [5]. Although at present these findings
will not yet impact the treatment plan, in the future early re-
sponse prediction using functional imaging methods such as
PET may be of great clinical value as this may allow for early
treatment adaptations to enhance the chance of a good ther-
apeutic response.2.4. Magnetic resonance imaging (MRI)
MRI using modern phased-array external coils offers the
advantages of an excellent soft tissue contrast, high spatial
resolution and a large field of view. This makes MRI an invalu-
able technique for detailed morphological information on
both the tumour and its extension into the surrounding mes-
orectal compartment and neighbouring organs. MRI is the
recommended imaging method for staging and restaging of
rectal cancer in most European countries. The following sec-
tions will elaborate on aspects of MRI relevant for rectal can-
cer imaging, including the optimal MR protocol.3. MRI protocol for the staging of rectal cancer
3.1. Patient preparation
MRI using phased array external coils has become the stan-
dard technique for state-of-the-art imaging of rectal cancer.
MRI using an endorectal coil, although similar in performance
to EUS for the assessment of superficial (T1 and T2) tumours,
has not gained worldwide acceptance. First, endorectal MRI is
more cumbersome in application and less patient-friendlythan EUS and does not allow for simultaneous tumour biop-
sies, which is an added advantage of EUS. Furthermore, coil
positioning for endorectal MRI can be very difficult, particu-
larly in high and/or stenosing tumours. For phased array
MRI routine use of spasmolytics or bowel preparation is not
required. Nevertheless, occasional use of spasmolytics may
be helpful when severe bowel movement artefacts are already
visible on the (sagittal) planning scan, particularly in patients
presenting with tumours situated high in the rectum and
thus nearer to adjacent small bowel loops. Use of endorectal
contrast or filling (for example using ultrasonography gel) is
not recommended as part of standard clinical routine. The
main argument for applying endorectal filling is to allow a
more confident assessment of the exact tumour location
within the lumen, particularly in smaller-sized tumours [6].
However, given the fact that information on the tumour loca-
tion is given during endoscopy, the use of intraluminal filling
does not outweigh its potential disadvantages. Apart from the
patient burden, the introduction of endorectal contrast
causes stretching of the rectal wall which in turn compresses
the mesorectal compartment. Hence, rectal distension may
hamper the assessment of lymph nodes in the mesorectal
compartment and can also result in overestimation of tumour
invasion of the mesorectal fascia [7], which are in fact two of
the principal important factors that need to be evaluated with
MRI (see also section below on assessing risk factors for local
recurrence).
3.2. Imaging sequences
A standard rectal MR protocol should consists of multiplanar
T2-weighted Fast Spin Echo (T2W FSE) sequences, since these
offer an optimal soft tissue contrast between the tumour, the
mesorectal fat and the mesorectal fascia surrounding the
mesorectal compartment. The optimal slice thickness of the
T2W sequences ranges between 1 and 3 mm and should not
exceed 5 mm. A sagittal T2W sequence should be first ob-
tained in order to localise the tumour and allow for proper
angulation of the axial and coronal planes. It is of the utmost
importance that the axial and coronal planes are angled ex-
actly perpendicular and parallel to the longitudinal tumour
axis (as identified on the sagittal scan) so that the relationship
of the tumour with the surrounding organs and structures
can reliably be assessed. In very low rectal tumours the coro-
nal sequences should be angled parallel to the anal canal to
establish the relation of the tumour to the pelvic floor and
anal sphincter musculature. There is no solid evidence yet
for the routine use of additional sequences other than T2W
sequences in three planes. Fat-suppression sequences are
not recommended since they do not allow a proper apprecia-
tion of the mesorectal fascia. A (non-enhanced) T1-weighted
sequence may be useful for the evaluation of coincidental
findings in other pelvic organs, but is not required for the
staging of rectal cancer. There is no solid indication for the
administration of intravenous contrast agents. Gadolinium
contrast was shown not to be beneficial for T-stage and
CRM evaluation [8]. Although experimental studies have
investigated the use of dynamic contrast-enhanced MRI and
lymph-node-specific contrasts, at the time of writing these
techniques are not yet recommended for daily clinical
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sequences have so far been obtained mainly in research pro-
tocol settings, although there is growing evidence that the
addition of DWI may be valuable, especially in the restaging
setting after chemoradiation to re-evaluate the primary tu-
mour (see also section on diffusion-weighted MRI below).
4. Assessing the risk factors for local
recurrence using MRI
There are four main risk factors for developing a local recur-
rence, which are used to determine treatment planning: (1)
the tumour height (low, middle or upper third of the rectum),
(2) the local extent of the tumour (T-stage), (3) involvement of
the mesorectal fascia and (4) nodal involvement (N-stage).
4.1. Tumour height
Tumour height is an important parameter as low rectal tu-
mours (e.g. within the first 5 cm above the anal verge) are
known to have a worse prognosis than tumours situated
higher in the rectum. As a result of the distal tapering of
the mesorectum and consequent decrease of the thickness
of the fat plane surrounding the rectum, low tumours have
a relatively close relationship with the mesorectal fascia,
the pelvic floor muscles and the anterior pelvic organs (pros-
tate/seminal vesicles in men and vagina/uterus in women)
and have a higher risk of invasion.
Although the tumour height can be accurately measured
on MRI (often using the anorectal junction as a reference
point) the surgeon is generally already aware of the tumour
location from his endoscopic assessment, so often this is
not one of the strong arguments to perform imaging. In the
United States, the location of the tumour in relation to the
peritoneal reflection is often used as an additional landmark
to determine whether a patient requires neoadjuvant treat-
ment (if the tumour is below the peritoneal reflection) or
not (if the tumour is above the peritoneal reflection). The level
of the tumour in relation to the peritoneal reflection can be
accurately assessed using MRI [12].
4.2. Tumour (T-)stage
The overall reported accuracy for T-stage prediction with
phased array MRI varies between 67% and 83% [13]. The main
strength of MRI is the evaluation of large T3 tumours that
penetrate the muscular rectal wall and T4 tumours invading
adjacent organs, for which MRI has been reported to achieve
sensitivities and specificities of 74% and 76% (in T3 tumours)
and 82% and 96% (in T4 tumours), respectively [14]. MRI, how-
ever, is known to have difficulties in differentiating between
superficial T1 and T2 tumours. As opposed to EUS, with MRI
it is not possible to separately appreciate all three layers of
the rectal wall. The submucosal layer of the rectal wall is
not visualised on phased-array MRI (except when there is oe-
dema). Hence, differentiation between a T1 tumour limited to
the submucosa and a T2 tumour penetrating the muscularis
propria is not feasible. Consequently, EUS remains the corner-
stone technique for the selection of superficial T1 tumours
that can be considered for local excision. Another limitationof MRI (as well as EUS) is the differentiation between T2 and
borderline T3 tumours. Desmoplastic strands into the meso-
rectal fat in a T2 tumour without actual tumour infiltration
cannot be discriminated from desmoplastic reactions con-
taining tumour nests indicating a T3 tumour. In practice, this
results in the over-staging of a considerable number (up to
40%) of T2 tumours because radiologists tend to err ‘on the
safe side’ rather than risk under-staging [15,16]. Only when
the bowel wall on T2-weighted MR images is visualised as a
completely intact hypointense line around the tumour does
this indicate an intact muscular bowel layer, which can be
used as a reliable predictor for the tumour being limited to
the bowel wall (T1–2) with a PPV of 86–91% [17].
4.3. The mesorectal fascia (MRF)
Preoperative knowledge of tumour involvement of the MRF is
critical in order to determine whether it will be possible to ob-
tain a complete resection of the tumour. Assessment of the
MRF is only relevant in the case of a T3 or T4 tumour. When
it is established that the tumour is surrounded by an intact
bowel wall (indicating a T1–2 tumour) the MRF will never be
involved [13]. In the case of a PT3 tumour, the relation be-
tween the tumour and the MRF should be evaluated (i.e. the
circumferential resection margin at TME). When the tumour
invades the MRF or extends within a margin of <1 mm, the
MRF is involved. It is well known that MRI is very accurate
in evaluating tumoural involvement of the MRF. In a large pa-
tient cohort the MERCURY study group found an overall accu-
racy of >90% for MRI in predicting tumour involvement of the
MRF [18]. In a meta-analysis of seven individual reports
(including the MERCURY cohort) sensitivities and specificities
for MRI ranged between 60% and 88% and between 73% and
100% respectively [19].
4.4. Lymph nodes and extramural venous invasion (EMVI)
In addition to MRF involvement, lymph-node status com-
prises one of the main factors that determine the necessity
for the addition of neoadjuvant radiotherapy and/or chemo-
therapy. Unfortunately, so far MRI, EUS and CT have not
proved to be sufficiently accurate to determine the nodal sta-
tus. Themain problem is that imaging relies on nodal size (i.e.
short axis diameter) as the main criterion to discriminate be-
tween benign andmetastatic nodes. In rectal cancer in partic-
ular it is known that size is not a reliable predictor because
metastases frequently occur in small (<5 mm) nodes [20]. As
a result there is no reliable size threshold, and cut-off sizes
have been reported ranging from ‘any visible node’ to
>1 cm. In practice, the chosen size threshold depends mainly
on the desired balance between sensitivity and specificity,
more often favouring the former. Two meta-analyses that
analysed the pooled data from nodal imaging studies using
size criteria on EUS, CTor MRI showed similarly poor sensitiv-
ities and specificities in the range of 55–78% [14,19]. Some
authors have shown that the use of morphological criteria
in addition to size can improve the diagnostic performance
of imaging in assessing the lymph nodes with reported sensi-
tivities of 36–85% and specificities of 95–100% [21,22]. Nodes
with a sharply delineated border and homogeneous signal
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ular border and heterogeneous signal pattern are more likely
to be involved. These criteria have not, however, been widely
implemented into clinical practice, probably partly because
these features are quite difficult to evaluate in very small
nodes (62–3 mm). Apart from nodes within the lower and
mid mesorectal compartment, a report on rectal cancer
should also mention any suspicious nodes that are located
high in the mesorectum, along the superior rectal vessels,
as well as outside the mesorectum below the internal iliac
bifurcation at the root of the medial rectal vessels (the lateral
nodes), as involvement of these nodes harbours a higher risk
for distant and local recurrence and will need to be included
in the radiation field and/or removed with surgery.
Extramural venous (or vascular) invasion (EMVI) is the
presence of tumour invasion in the veins in the vicinity of
the tumour. EMVI, as established at histology, is known to
be associated with an increased risk of local and distant
recurrence and an impaired overall survival [23]. As such,
EMVI is considered an important prognostic marker at histo-
pathology. It has been shown that the presence of EMVI can
be assessed on MRI based on the presence of tumoural signal
intensity within vessels surrounding the rectum, or the pres-
ence of a nodular expansion or irregular vessel contour as cri-
teria [24]. It has furthermore been suggested that the
presence of EMVI may be related to the presence of nodular
disease, since lymphatic vessels run parallel to blood vessels
and may therefore be simultaneously invaded by the tumour.
In one report, a high EMVI score had been shown to predict
the presence of N2 disease with low to moderate sensitivity
(56%) and relatively high specificity (81%) [25]. The exact cor-
relation between EMVI and the presence of nodal metastases,
however, is not well established.
5. Restaging after neoadjuvant treatment
Traditionally, restaging with MRI after neoadjuvant treatment
had only a limited role, since the surgeon would proceed with
the original surgical treatment plan as determined on the ba-
sis of the primary staging MRI, regardless of the response
after chemoradiotherapy. Nowadays the role of restaging with
imaging is emerging as surgeons recognise its value for plan-
ning the surgical approach. For example, if a tumour is shown
to have downsized and retracted from initially invaded organs
and/or the MRF, a standard total mesorectal excision (TME) in-
stead of a more extended pelvic resection can be considered.
Retraction from the anal canal may allow for sphincter-
preserving surgery. Although still controversial, alternative
treatments such as a local, transanal excision or deferral from
surgery (a so called ‘wait-and-see policy) in the selected group
of very good or complete responding patients have been re-
ported by several groups with very promising results [26,27].
This paradigm shift in treatment puts the relevance of a
restaging with imaging into a whole new perspective.
Although the importance of a restaging MRI is acknowledged,
there is no clear consensus on what should be the time inter-
val between the completion of the neoadjuvant treatment
and the response evaluation with imaging. It is believed that
a longer interval (i.e. at least 6 weeks) provides better insight
into the final treatment response.5.1. Residual tumour versus fibrosis
Basically, a report of a restaging MRI should include an
assessment of the same items as during primary staging
(i.e. T-stage, MRF and N-stage). However, an important addi-
tional challenge in the restaging setting is the interpretation
of post-treatment fibrosis. As a result of the chemoradiother-
apy the tumour and nodes shrink and become fibrotic. On
post-treatment T2W MRI this fibrosis is visualised as a hypo-
intense bowel thickening at the previous site of the primary
tumour or in the nodes. It is extremely difficult to differenti-
ate between mere fibrosis and fibrotic tissues still containing
(small) islets of residual tumour. Because radiologists will
tend to over-stage rather than under-stage, relatively high
over-staging rates (up to 50%) as compared with primary stag-
ing have been reported. Overall accuracies for determining
the T-stage after chemoradiotherapy (the yT-stage) range be-
tween 43% and 60% [28,29]. More favourable results have been
suggested for the selection of patients with a ‘good’ tumour
response (i.e. tumour down-staging to yT0–2). It has been
shown that post-CRT MRI can accurately predict tumours that
are confined to the bowel wall (ypT0–2) with PPVs of 86–91%
and NPVs of 70–75% [17]. However, for the specific selection
of patients with a complete tumour response (yT0) results –
in particular PPV – are much poorer, and up to 80% of patients
with a complete response are over-staged as having residual
tumour [15,30]. This suggests that, using standard MRI, it will
be very difficult to select patients for a ‘wait-and-see’ policy.
5.2. Tumour regression from the MRF
Similar to restaging of the tumour, the reassessment of the
MRF is hampered mainly by difficulties in interpreting post-
treatment fibrosis. In the case of residual fibrotic involvement
of the mesorectal fascia, it is difficult to determine whether
there is still actual tumour involvement and a substantial
number of patients will be over-staged. However, there are
some patterns that can help radiologists in confidently
assessing tumour clearance from a previously involved MRF.
If a fatpad of >2 mm reappears between the tumour and
MRF, we can be confident that the MRF will be free of tumour.
If there is only some residual (fibrotic) stranding into the MRF,
the MRF will also be likely to be free of tumour [31]. NPVs in
the range of 91–100% have been reported for reassessment
of MRF involvement after CRT indicating that the patients
with a free MRF can be reliably selected. PPVs, however, are
much lower (ranging between 44 and 68%), reflecting the
over-staging problems described above [18,28,31]. Park et al.
suggested that the evaluation of tumour clearance from the
MRF after CRT may be improved by the addition of diffu-
sion-weighted imaging, although these results have not (yet)
been confirmed by other studies [32].
5.3. Lymph nodes and EMVI after chemoradiation
As a result of chemoradiation treatment the majority of the
lymph nodes will decrease in size or even completely disap-
pear. Hence, the median number and size of lymph nodes
after CRT is significantly lower than at primary staging. The
main aim of re-evaluating the nodal stage after CRT is to
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inside but also outside the mesorectum, or if all initially sus-
picious nodes have become sterilised. In the latter case, a pa-
tient with a concomitantly good response of his primary
tumourmay be a candidate for organ-saving treatments (local
excision or wait-and-see), yet at the time of writing this is still
within the scope of clinical trials and not clinical routine. A
careful comparison of nodes before and after chemoradiation
is of crucial importance when interpreting nodes on post-CRT
MRI. Also, a re-evaluation of any initially suspicious extra-
mesorectal nodes should be performed in order to determine
whether a lateral lymph-node dissection will be required. The
diagnostic performance of post-chemoradiation MRI for
restaging of the nodes is reported to be equal or slightly better
than with primary staging MRI, with accuracies varying from
64% to 88% [28,33,34]. The criteria used for the restaging of
nodes are similar to those used for primary nodal staging
(size and, to a lesser extent, the nodal border and signal inten-
sity), but it has been suggested by some authors that size cri-
teria work better in the restaging setting. A possible
explanation for this is that many irradiated nodes disappear,
and of the remaining small nodes over 80% are sterilised [35].
Hence, nodes that remain large in size after CRT are more
likely to be malignant.
There is no evidence (yet) to support the benefit of the re-
evaluation of EMVI after CRT. In currently available literature
EMVI has been assessed mainly in patients undergoing
immediate surgery (without preoperative treatment). In the
reports where patients undergoing neoadjuvant treatment
were included, no subset analyses were performed to specif-
ically investigate the value of assessing EMVI after preopera-
tive CRT.
6. Future perspectives
The time has passed when imaging was used to only provide
information on tumour morphology. Functional imaging
techniques give more comprehensive information on tumour
morphology and underlying tissue characteristics. Some of
these imaging biomarkers have already been implemented
into clinical protocols, others are still under investigation.
Multiparametric imaging in rectal cancer patients will signif-
icantly improve the radiologist’s performance, in particular
for treatment response evaluation. Apart from that, technical
developments in MR scanner hardware allow for innovative
moving table techniques which generate whole-body MR
images complementary to whole-body PET. The clinical intro-
duction of hybrid PET–MR scanners combining both morpho-
logical and functional whole-body imaging within one single
examination is the beginning of a new era.
6.1. Diffusion-weighted MRI (DWI)
One of the most promising functional MR techniques for
oncological imaging is diffusion-weighted MRI (DWI).
Although originally used for the assessment of brain ischae-
mia, body applications of DWI are now also increasingly
beginning to set the pace. DWI uses differences in the move-
ment (‘diffusion’) of water protons between tissues with adifferent cellular density to differentiate between tumoural
and non-tumoural tissues. Moreover, DWI can provide quan-
tifiable data reflecting a tissue’s cellular structure, referred to
as the apparent diffusion coefficient (ADC). Both the visual
assessment of diffusion images, as well as the quantitative
measurement of ADC, have shown great potential for rectal
cancer imaging, in particular for the evaluation of the thera-
peutic response of rectal tumours after chemoradiotherapy.
It has been shown by several authors that, compared with
standard MRI, DWI offers significantly better diagnostic per-
formance for the selection of patients with a good or com-
plete response of their primary tumour after CRT, with
reported AUCs up to 0.88 [30,36,37]. Although at present
DWI is being investigated mainly in research settings and
its true clinical potential has yet to be proven, DWI sequences
are already frequently implemented into clinical protocols.
6.2. Dynamic and lymph node contrast-enhanced MRI
Measurements of tumour microvascular perfusion are known
to be valuable for cancer detection and treatment monitoring.
Dynamic contrast-enhanced (DCE) or ‘perfusion’ MRI tech-
niques could be a promising adjunct to morphological MRI
in early response prediction. A pre-treatment measured Ktrans
perfusion parameter has been shown in early studies to be
valuable in distinguishing between patients with good or poor
responses. Another potentially interesting topic in the field of
lymph node imaging is the use of ‘lymph-node-specific’ MR
contrast agents. Very promising results have been shown for
the use of ultrasmall particles of iron oxide (USPIO), but this
contrast has so far not been approved by the Food and Drug
Administration for clinical use. Other MR contrasts such as
gadofosveset-trisodium are currently being investigated.
Although initial results seem very encouraging, these will
need to be confirmed in large multicentre studies to warrant
implementation into clinics.
7. Conclusions and recommendations
Since the treatment for rectal cancer has emerged from a
‘one-size-fits-all’ strategy towards a personalised treatment
plan based on a patient’s individual tumour risk profile, the
role of the radiologist within the multidisciplinary team has
changed. The radiologist now plays a full consulting role,
and his imaging findings can influence treatment manage-
ment. The current role of CTs (and PET–CTs) is mainly for
the assessment of distant tumour spread. For local tumour
staging MRI and EUS are the main players. EUS remains the
best technique for the evaluation of low-risk, superficial tu-
mours (T1–2) that may primarily be treated with (local) exci-
sion. For the evaluation of larger tumours, in particular for
the assessment of large tumours that have a risk for invasion
of the mesorectal fascia and neighbouring pelvic organs, MRI
is the technique of first choice. Although lymph-node status
is an important determinant for treatment, none of the cur-
rently available imaging modalities (CT, MRI or EUS) is suffi-
ciently accurate to reliably assess the nodes.
The role of imaging for restaging after neoadjuvant che-
moradiotherapy is rapidly advancing. While previously the
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findings of primary staging, this plan may now be altered
on the basis of the response of the tumour to CRT and the
new findings at restaging imaging. The main difficulty after
chemoradiotherapy is the differentiation on imaging between
small residual disease and post-radiation fibrosis. Together
with the dilemma of accurate nodal staging, these two chal-
lenges need to be addressed in the coming years. New hybrid
and versatile MRI techniques, however, are on the horizon
that may be able to offer a solution.
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